Pivotal Study in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer

NCT03786094 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

432

Enrollment

INDUSTRY

Sponsor class

Stopped The study was halted early due to failure to meet the primary endpoint.

Conditions

Metastatic Breast Cancer
Locally Recurrent Breast Cancer

Interventions

DRUG: Eribulin
DRUG: Balixafortide

Sponsor

Spexis AG